The role of fulvestrant in endometrial cancer

Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma

(2015) Stefano Bogliolo et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Deubiquitinases and the new therapeutic opportunities offered to cancer

(2015) R. Pfoh et al.   ENDOCRINE-RELATED CANCER

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

(2015) Brian M. Slomovitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges

(2015) Michelle M. Boisen et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) N. Colombo et al.   ANNALS OF ONCOLOGY

Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie

(2013) Günter Emons et al.   GYNECOLOGIC ONCOLOGY

ERα Phosphorylation at Y537 by Src Triggers E6-AP-ERα Binding, ERα Ubiquitylation, Promoter Occupancy, and Target Gene Expression

(2012) Jun Sun et al.   MOLECULAR ENDOCRINOLOGY

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

(2011) Suzanne E. Wardell et al.   BIOCHEMICAL PHARMACOLOGY

Fulvestrant

(2011) Jamie D. Croxtall et al.   DRUGS

C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-  and the critical period hypothesis of estrogen neuroprotection

(2011) Q.-g. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study

(2010) Allan L. Covens et al.   GYNECOLOGIC ONCOLOGY

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

OTU Domain-containing Ubiquitin Aldehyde-binding Protein 1 (OTUB1) Deubiquitinates Estrogen Receptor (ER) α and Affects ERα Transcriptional Activity

(2009) Vladimir Stanišić et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gene expression profiling in Ishikawa cells: A fingerprint for estrogen active compounds

(2009) Kathleen Boehme et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY